Paul Buderath
Overview
Explore the profile of Paul Buderath including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1505
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buderath P, Dang T, Kimmig R
J Gynecol Oncol
. 2024 Jun;
36(1):e13.
PMID: 38945527
Objective: Cancer-field surgery by peritoneal mesometrial resection and targeted compartmental lymphadenectomy (PMMR+TCL) for the treatment of endometrial cancer (EC) aims at optimal locoregional tumor control without the need for adjuvant...
2.
Kimmig R, Thangarajah F, Buderath P
Best Pract Res Clin Obstet Gynaecol
. 2024 Feb;
94:102483.
PMID: 38401483
Anatomical and functional aspects of the lymphatic drainage of the uterine corpus in endometrial cancer are demonstrated. Main lymphatic pathway runs along the upper pelvic pathway from the uterine artery...
3.
Buderath P, Elgharib M, Kimmig R
Arch Gynecol Obstet
. 2024 Jan;
309(4):1569-1574.
PMID: 38217762
Objective: Peritoneal mesometrial resection (PMMR) plus targeted compartmental lymphadenectomy (TCL) aims at removal of the locoregional cancer field in endometrial cancer (EC). Optimal locoregional control without adjuvant radiotherapy should be...
4.
Mairinger E, Wessolly M, Buderath P, Borchert S, Henrich L, Mach P, et al.
Front Oncol
. 2023 Nov;
13:1252700.
PMID: 38023247
Background: The underlying mechanism of high T-cell presence as a favorable prognostic factor in high-grade serous ovarian carcinoma (HGSOC) is not yet understood. In addition to immune cells, various cofactors...
5.
Klar M, Plett H, Harter P, Heitz F, Kommoss S, Hartkopf A, et al.
J Surg Oncol
. 2023 Mar;
128(1):111-118.
PMID: 36975108
Background: Malignant sex cord-stromal cell tumours (SCST) account for only 7% of ovarian malignancies. The Arbeitsgemeinschaft fuer Gynaekologische Onkologie (AGO) study group has established a clinicopathological database to provide an...
6.
Roser E, Harter P, Zocholl D, Denschlag D, Chekerov R, Wimberger P, et al.
Int J Gynecol Cancer
. 2023 Jan;
33(2):223-230.
PMID: 36631151
Objective: Gynecological sarcomas account for 3% of all gynecological malignancies and are associated with a poor prognosis. Due to the rarity and heterogeneity of gynecological sarcomas there is still no...
7.
Buderath P, Kimmig R, Dominowski L, Mach P
Arch Gynecol Obstet
. 2022 Oct;
307(3):807-812.
PMID: 36301346
Introduction: Minimally invasive (MI) surgery has long been established as a standard for hysterectomy in benign conditions. Robotic surgery is generally seen as equivalent to conventional laparoscopy in terms of...
8.
Mach P, Kaufold C, Rusch P, Kimmig R, Buderath P
Arch Gynecol Obstet
. 2022 Aug;
306(6):2009-2015.
PMID: 35974180
Purpose: Sarcopenia has been established as the "gold standard" for the treatment of pelvic organ prolapse (POP). Minimal invasive laparoscopy can help to reduce the risks of open access surgery....
9.
Stergiopoulou D, Markou A, Giannopoulou L, Buderath P, Balgkouranidou I, Xenidis N, et al.
Cancers (Basel)
. 2022 Aug;
14(15).
PMID: 35954453
mutations have been recently associated with resistance to endocrine therapy in metastatic breast cancer and their detection has led to the development and current evaluation of novel, highly promising therapeutic...
10.
Wessolly M, Mairinger E, Borchert S, Bankfalvi A, Mach P, Schmid K, et al.
Front Oncol
. 2022 Mar;
12:798680.
PMID: 35311102
Background: High-grade serous ovarian cancer (HGSOC) is the predominant and deadliest form of ovarian cancer. Some of its histological subtypes can be distinguished by frequent occurrence of cancer-associated myofibroblasts (CAFs)...